Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $778,387 | 37 | 100.0% |
| Food and Beverage | $121.33 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Roche Diagnostics Corporation | $638,387 | 30 | $0 (2024) |
| Novavax Inc | $140,000 | 7 | $0 (2023) |
| Gilead Sciences, Inc. | $121.33 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98,387 | 6 | Roche Diagnostics Corporation ($98,387) |
| 2023 | $320,121 | 17 | Roche Diagnostics Corporation ($180,000) |
| 2022 | $280,000 | 12 | Roche Diagnostics Corporation ($280,000) |
| 2021 | $80,000 | 3 | Roche Diagnostics Corporation ($80,000) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/08/2024 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $18,387.00 | General |
| Category: None | ||||||
| 07/16/2024 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $15,000.00 | General |
| Category: None | ||||||
| 06/19/2024 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $15,000.00 | General |
| Category: None | ||||||
| 05/22/2024 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $15,000.00 | General |
| Category: None | ||||||
| 04/09/2024 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $15,000.00 | General |
| Category: None | ||||||
| 01/02/2024 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 12/19/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 12/12/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 10/25/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 10/09/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $121.33 | General |
| 09/27/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 08/18/2023 | Novavax Inc | NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: Vaccine | ||||||
| 08/15/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 07/14/2023 | Novavax Inc | NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: Vaccine | ||||||
| 07/06/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 06/16/2023 | Novavax Inc | NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: Vaccine | ||||||
| 06/13/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 05/12/2023 | Novavax Inc | NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: Vaccine | ||||||
| 04/17/2023 | Novavax Inc | NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: Vaccine | ||||||
| 03/13/2023 | Novavax Inc | NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: Vaccine | ||||||
| 03/09/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 02/13/2023 | Novavax Inc | NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: Vaccine | ||||||
| 01/25/2023 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 12/14/2022 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
| 12/01/2022 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| Category: None | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 110 | 124 | $21,104 | $9,500 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 32 | 46 | $12,604 | $4,900 | 38.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 22 | 22 | $5,320 | $1,914 | 36.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 14 | 14 | $1,050 | $1,007 | 95.9% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 15 | 15 | $850.00 | $650.10 | 76.5% |
| 0044A | Adm sarscov2 5mcg/0.5ml bst | Office | 2023 | 14 | 14 | $630.00 | $606.76 | 96.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 13 | 13 | $650.00 | $422.50 | 65.0% |
About Dr. Robert Redfield, M.D
Dr. Robert Redfield, M.D is a Infectious Disease healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568402717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Redfield, M.D has received a total of $778,508 in payments from pharmaceutical and medical device companies, with $98,387 received in 2024. These payments were reported across 38 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($778,387).
As a Medicare-enrolled provider, Redfield has provided services to 110 Medicare beneficiaries, totaling 124 services with total Medicare billing of $9,500. Data is available for 1 year (2023–2023), covering 6 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Baltimore, MD
- Active Since 06/07/2006
- Last Updated 11/16/2010
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1568402717
Products in Payments
- NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) $140,000
- Non-Product Specific (Device) $60,000
- KIT COBAS 6800/8800 SARS-COV-2/FLU 384T (Device) $20,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Baltimore
Luciana Borio, M.d, M.D
Infectious Disease — Payments: $579,903
Dr. Robert Edelman, M.d, M.D
Infectious Disease — Payments: $287,881
Charles Flexner, M.d, M.D
Infectious Disease — Payments: $176,847
Dr. Kjell Wiberg, Md, MD
Infectious Disease — Payments: $137,156
Sara Cosgrove, M.d, M.D
Infectious Disease — Payments: $91,406
Allison Agwu, M.d, M.D
Infectious Disease — Payments: $70,557